Physician profile
Navin Verma
NPI 1962524884
$19,566.21
in general payments reported to CMS, 2019-2025
75 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,428 · 2020: $2,070 · 2021: $2,764 · 2022: $2,802 · 2023: $3,024 · 2024: $3,742 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,414 · Travel and Lodging: $998 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,414.02 |
| Travel and Lodging | $997.72 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.72 | 2019-2025 | Botox, Duopa, Qulipta |
| Calliditas Therapeutics US INC. | $1,357.72 | 2024 | |
| Genzyme Corporation | $1,114.30 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $956.31 | 2020-2025 | Xywav |
| Lilly USA, LLC | $920.79 | 2019-2025 | Amyvid, Kisunla, Zepbound |
| Harmony Biosciences LLC | $866.41 | 2020-2025 | Wakix |
| Amgen INC. | $791.67 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $742.09 | 2019-2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $696.42 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $677.07 | 2019-2023 | Austedo, Austedo Xr |
| Horizon Therapeutics Plc | $674.87 | 2021-2023 | Uplizna |
| Allergan, INC. | $659.84 | 2019-2022 | |
| Ucb, INC. | $647.40 | 2019-2025 | Rystiggo |
| Biogen, INC. | $518.68 | 2019-2025 | Leqembi, Spinraza, Tysabri |
| Genentech USA, INC. | $438.02 | 2019-2024 | Ocrevus, Ocrevus Zunovo, Evrysdi |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.